#	Pagina
attuale pagina	/open-h2020/projects/210531/index.html

Opendata, web and dolomites

NAFLDcure

A novel pharmaceutical treatment for nonalcoholic fatty liver disease

Total Cost €

EC-Contrib. €

Partnership

Views

NAFLDcure project word cloud

Explore the words cloud of the NAFLDcure project. It provides you a very rough idea of what is the project "NAFLDcure" about.

cirrhosis mir pharmacological anti 132 microrna nash untreatable models oligonucleotide discovery modifying poorly liver brain accumulation cancer excessive inherited mouse disease nonalcoholic excess progresses fatty steatohepatitis antisense corresponding treatment pathogenesis serious triglycerides largely initiates discovered acquired links reverses development pharmaceutical suppression metabolism nafld therapeutic

Project "NAFLDcure" data sheet

The following table provides information about the project.

Coordinator	THE HEBREW UNIVERSITY OF JERUSALEM Organization address address: EDMOND J SAFRA CAMPUS GIVAT RAM city: JERUSALEM postcode: 91904 website: www.huji.ac.il contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Israel [IL]
Total cost	150˙000 €
EC max contribution	150˙000 € (100%)
Programme	1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
Code Call	ERC-2016-PoC
Funding Scheme	ERC-POC
Starting year	2017
Duration (year-month-day)	from 2017-06-01 to 2018-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	THE HEBREW UNIVERSITY OF JERUSALEM THE HEBREW UNIVERSITY OF JERUSALEM Organization address address: EDMOND J SAFRA CAMPUS GIVAT RAM city: JERUSALEM postcode: 91904 website: www.huji.ac.il contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IL (JERUSALEM)	coordinator	150˙000.00

Map

Project objective

Development of anti-microRNA therapeutic for nonalcoholic fatty liver disease Nonalcoholic fatty liver disease (NAFLD) initiates with excessive accumulation of liver triglycerides and progresses to nonalcoholic steatohepatitis (NASH), cirrhosis and liver cancer while also modifying brain metabolism. However, NAFLD pathogenesis, the corresponding impact on the brain and the links between them, are poorly understood. In addition NAFLD is largely untreatable. We have discovered that excess microRNA (miR)-132 initiates NAFLD and that miR-132 suppression by oligonucleotide antisense treatment effectively reverses NAFLD in acquired and inherited mouse models. Here we to develop this discovery as a novel and effective pharmaceutical for the treatment of NAFLD, a serious and widespread disease for which there is at present no pharmacological treatment.

Publications

List of publications.
year	authors and title	journal	last update
2018	Geula Hanin, Nadav Yayon, Yonat Tzur, Rotem Haviv, Estelle R Bennett, Shiran Udi, Yoganathan R Krishnamoorthy, Eleni Kotsiliti, Rivka Zangen, Ben Efron, Joseph Tam, Orit Pappo, Eyal Shteyer, Eli Pikarsky, Mathias Heikenwalder, David S Greenberg, Hermona Soreq miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression published pages: 1124-1134, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2016-312869	Gut 67/6	2019-05-28

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NAFLDCURE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NAFLDCURE" are provided by the European Opendata Portal: CORDIS opendata.